<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03926286</url>
  </required_header>
  <id_info>
    <org_study_id>20170733</org_study_id>
    <nct_id>NCT03926286</nct_id>
  </id_info>
  <brief_title>Fecal Microbial Transplant (FMT) for Sjogrens Syndrome</brief_title>
  <official_title>Fecal Microbial Transplant for Sjogrens Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sjogrens Syndrome Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Microbiome Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label study to evaluate the effect of Fecal Microbiota Transplantation (FMT)
      on the gut microbiome and Systemic parameters.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with reported adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>7 months</time_frame>
    <description>As an evaluation of the safety of FMT, the number of participants with reported AEs and SAEs will be collected. All occurrences of AEs and SAEs, regardless of relatedness to FMT, will be reported and assessed by the clinician using the NIH CTCAE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with stable microbiome engraftment</measure>
    <time_frame>month 3</time_frame>
    <description>Engraftment will be analyzed via the Jensen-Shannon divergence (JSD). The engraftment scores will be the ratio between the donors and recipients at the bacterial genus level. Participants who successfully engraft will more closely resemble the donor microbial profile on JSD analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in dry eye symptoms</measure>
    <time_frame>baseline, 1 week, 1 month, 3 months</time_frame>
    <description>Dry eye symptoms will be measured by the Ocular Surface Disease Index (OSDI) Scale 0-100 Continuous with higher scores representing greater dry eye symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dry eye symptoms</measure>
    <time_frame>baseline, 1 week, 1 month, 3 months</time_frame>
    <description>Dry eye symptoms will be measured by the Dry Eye Questionnaire 5 (DEQ5) Scale Range 0-22 Continuous with a higher number representing greater symptomatology of dry eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diversity of bacterial communities</measure>
    <time_frame>Pre FMT, 3 months post FMT</time_frame>
    <description>This will be captured via high-throughput 16S gene sequencing using DNA extracted from stool specimens in study participants. The Shannon diversity index will be used as our primary measure of diversity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in system immune profiles as measured by T cell populations</measure>
    <time_frame>Pre-FMT, 1 Week, 1 Month, 3 months post FMT</time_frame>
    <description>System immune profiles will be evaluated by completing a comprehensive immuno-phenotypic profile from blood samples evaluating T cell populations including Th1, Th17, and T regulatory cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ocular and systemic symptoms as measured by the quality of life SF-12 Questionnaire</measure>
    <time_frame>Pre-FMT, 1 Week, 1 Month, 3 months post FMT</time_frame>
    <description>Ranges 0-100 with higher scores representing a better quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in self-reported ocular pain as assessed by the Numerical Rating Scale(NRS)</measure>
    <time_frame>Pre-FMT, 1 Week, 1 Month, 3 months post FMT</time_frame>
    <description>NRS Scoring Ranges from 0-10 with 0=no pain sensation and 10=the most intense eye pain imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in self-reported ocular pain as assessed by the Short-form McGill Pain Questionnaire(SFM-PQ)</measure>
    <time_frame>Pre-FMT, 1 Week, 1 Month, 3 months post FMT</time_frame>
    <description>SFM-PQ Scoring Ranges from 0-45 with zero to 45 with a higher score indicating more server eye pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in self-reported ocular pain as assessed by the Neuropathic Pain Symptom Inventory (NPSI)</measure>
    <time_frame>Pre-FMT, 1 Week, 1 Month, 3 months post FMT</time_frame>
    <description>NPSI Scoring Ranges from 0-100 with the higher score indicating the worse pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression as assessed by the Patient Health Questionnaire-9 (PHQ-9)</measure>
    <time_frame>Pre-FMT, 1 Week, 1 Month, 3 months post FMT</time_frame>
    <description>PHQ-9 scoring Ranges from 0-27 with the higher score indicating a greater degree of depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression as assessed by the Symptom Checklist 90 for Depression (SCL-90 Depression)</measure>
    <time_frame>Pre-FMT, 1 Week, 1 Month, 3 months post FMT</time_frame>
    <description>SCL-90 Depression scoring ranges from 0-4 with the higher score indicating a greater degree of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety as assessed by the Symptom Checklist 90 for Anxiety (SCL-90 Anxiety)</measure>
    <time_frame>Pre-FMT, 1 Week, 1 Month, 3 months post FMT</time_frame>
    <description>SCL-90 Anxiety scoring ranges from 0-4 with the higher score indicating a greater degree of anxiety.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Sjogren's Syndrome</condition>
  <arm_group>
    <arm_group_label>FMT for Sjogrens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FMT- active ingredient coming from participant's screening stool</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FMP-30</intervention_name>
    <description>FMP-30 containing frozen human fecal microbiota administered as (3) units of FMP30 enema on Day 0 and Week1</description>
    <arm_group_label>FMT for Sjogrens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Positive diagnosis of Sjogrens syndrome, defined by meeting two or more of the
             following three criteria:

               -  Positive serum anti-SS-A/Ro and/or anti-SS-B/La (or positive rheumatoid factor
                  and ANA ≥ 1:320)

               -  Labial salivary gland biopsy exhibiting focal lymphocytic sialadenitis with a
                  focus score ≥ focus/4 mm2

               -  Keratoconjunctivitis sicca with ocular staining score ≥ 3 (assuming that
                  individual is not currently using daily eye drops for glaucoma, and has not had
                  corneal surgery or cosmetic eyelid surgery in the last 5 years)

             Or by both of the following:

             Positive antibodies to one of the early markers of Sjogrens Syndrome:

               -  Anti-salivary gland protein 1 (SP1)

               -  Anti-carbonic anhydrase 6 (CA6)

               -  Parotid secretory protein (PSP) Ocular staining score ≥ 3

          2. Age ≥ 18 years at time of enrollment

          3. Able to provide signed and dated informed consent

          4. Women of child childbearing potential in sexual relationships with men must use an
             acceptable method of contraception§ from 30 days prior to enrollment until 4 weeks
             after completing study treatment.

          5. Males must agree to avoid impregnation of women during and for four weeks after
             completing study treatment through use of an acceptable method of contraception*.

               -  Includes, but is not limited to, barrier with additional spermicidal foam or
                  jelly, intrauterine device, hormonal contraception (started at least 30 days
                  prior to study enrollment), intercourse with men who underwent vasectomy.

                    -  Includes, but is not limited to, barrier with additional spermicidal foam or
                       jelly and vasectomy.

        Participant exclusion criteria

        Exclusion Criteria:

          1. Inability to provide informed consent and/or unable or unwilling to comply with
             protocol requirements.

          2. Antibiotics for at least 2 weeks prior to FMT.

          3. Active infection for &gt;15 days: bacteremia, urinary tract infection, pneumonia or
             abdominal collection.

          4. Known or suspected toxic megacolon and/or known small bowel ileus.

          5. Previous FMT

          6. Major gastrointestinal surgery (e.g. significant bowel resection) within 3 months
             before enrollment. This does not include appendectomy or cholecystectomy.

          7. History of total colectomy or bariatric surgery.

          8. Antibiotics for the treatment of an active infection or anticipated antibiotic use
             during trial duration.

          9. Concurrent intensive induction chemotherapy, radiation therapy or biological treatment
             for active malignancy.

         10. Expected life expectancy &lt; 6 months

         11. Patients with a history of severe anaphylactic or anaphylactoid food allergy.

         12. Solid organ transplant patients ≤ 90 days post-transplant or on active treatment for
             rejection.

         13. Neutropenia (&lt;500 neutrophils/mL) or other severe immunosuppression. Patients on
             monoclonal antibodies to B and T cells, anti-tumor necrosis factor, glucocorticoids,
             antimetabolites, calcineurin inhibitors may be enrolled after consultation with their
             medical doctor.

         14. Renal failure (GFR &lt;30 or dialysis)

         15. Human immunodeficiency virus+ controlled or not well controlled on antiretroviral
             therapy

         16. Regular probiotic supplement use within prior 2 weeks to enrollment

         17. Pregnancy or inability/unwillingness to use contraceptives.

         18. A condition that would jeopardize the safety or rights of the subject, would make it
             unlikely for the subject to complete the study, or would confound the results of the
             study.

         19. Exclusion on the discretion of the PI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anat Galor, MD, MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zaheer M, Wang C, Bian F, Yu Z, Hernandez H, de Souza RG, Simmons KT, Schady D, Swennes AG, Pflugfelder SC, Britton RA, de Paiva CS. Protective role of commensal bacteria in Sjögren Syndrome. J Autoimmun. 2018 Sep;93:45-56. doi: 10.1016/j.jaut.2018.06.004. Epub 2018 Jun 20.</citation>
    <PMID>29934134</PMID>
  </reference>
  <reference>
    <citation>De Luca F, Shoenfeld Y. The microbiome in autoimmune diseases. Clin Exp Immunol. 2019 Jan;195(1):74-85. doi: 10.1111/cei.13158. Review.</citation>
    <PMID>29920643</PMID>
  </reference>
  <reference>
    <citation>Wang C, Zaheer M, Bian F, Quach D, Swennes AG, Britton RA, Pflugfelder SC, de Paiva CS. Sjögren-Like Lacrimal Keratoconjunctivitis in Germ-Free Mice. Int J Mol Sci. 2018 Feb 13;19(2). pii: E565. doi: 10.3390/ijms19020565.</citation>
    <PMID>29438346</PMID>
  </reference>
  <reference>
    <citation>de Paiva CS, Jones DB, Stern ME, Bian F, Moore QL, Corbiere S, Streckfus CF, Hutchinson DS, Ajami NJ, Petrosino JF, Pflugfelder SC. Altered Mucosal Microbiome Diversity and Disease Severity in Sjögren Syndrome. Sci Rep. 2016 Apr 18;6:23561. doi: 10.1038/srep23561.</citation>
    <PMID>27087247</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Anat Galor</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Dry Eye</keyword>
  <keyword>Auto-Immune Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

